Clayman says the company's next 18 months are all about Zilretta, with further pipeline construction next up.
A plea for IT interoperability and a stinging criticism of the pharma industry over its lack of diversity were two highlights of yesterday's events.
Maker of Botox biosimilar Evolus files IPO; pharma execs expect major acquisitions in 2018; J&J and Bayer win Xarelto reversal verdict
How drugmakers should prepare for and respond to the forces poised to reshape the industry was a popular topic on day one of the 36th annual JP Morgan Healthcare Conference.
Shire considers splitting into two units; New Jersey finalizes physician-pharma gift limit; more biotech M&As expected in 2018
Allergan to cut 1,000 jobs; McKesson acquires RxCrossroads from CVS Health; Pfizer and Sangamo enter collaboration to develop ALS gene therapy
VP of investor relations Teri Loxam will take over Ambrose's role in January.
Pharma R&D return on investment falls to eight-year low; FDA approves Pfizer's biosimilar to J&J's Remicade; Novartis to downsize generics business
FDA approves first topical skin growth treatment; Teva to cut 14,000 jobs; Novartis Oncology CEO resigns
The VP of market access at Mitsubishi Tanabe Pharma America discusses driving access and bringing to market the first FDA-approved ALS drug in years.
The drugmaker named William Huyett as COO and Gina Consylman as SVP and CFO.
Whatever REDUCE-IT ultimately reveals (results from the completed study are expected in Q2 or Q3 2018), Salyer maintains Amarin has "a great story to tell, with or without the data."
FDA approves Novo's diabetes drug; Walgreens undergoes rebranding in the wake of CVS-Aetna merger; pharma increasingly transparent about clinical trial data
It's the experiences we bring to life, rather than the things we create, that build value, gain trust, and earn loyalty.
Teva to cut thousands of U.S. jobs; Regeneron drops Eylea combo drug development; insurers, drugstores, and hospitals increasingly teaming up
Only 2.6% of board members in Standard & Poor's 1,500 firms have marketing experience.
FDA approves first digital pill; biotech companies race to develop cancer-fighting microbiome drugs; Loxo and Bayer reach $1.55 billion deal for rare cancer drugs
Midway through Campaign's audience with Publicis Groupe's Maurice Lévy, a heavily French-accented voice exclaims, "Now it is time for the real boss to arrive."
The divisional VP and head of public affairs has seen it all, including the transformation from a traditional comms organization to a more dynamic and content-led group.
Trade group PhRMA's CEO talks about his first year in the job amid public outrage about price gouging.
The Paris-based pharma company debuted a brand campaign and signature last week.
J&J reports 15% lift in pharma sales in Q3; Apple reportedly considers buying medical clinics; survey finds need for digital investment in payer marketing
The association said it is preparing for new FDA approvals for therapies that treat central nervous system and muscular system diseases.
The communications team, led by Jeff Winton, is again researching Astellas' reputation for an updated picture on where the campaign has gotten them so far.
The successes of these pharma execs show that there's no one path to professional bliss.
Management turnover has brought the opportunity to keep up the pressure.
They are tasked with addressing an increasingly tough payer environment and ongoing criticism of the industry's drug-pricing practices.
What is second nature to most marketers may not be well understood by healthcare professionals who have spent their careers as physicians, researchers, or caregivers.
Novartis CEO Joe Jimenez to step down; Sanofi ends R&D plans for Zika vaccine; oncologists still struggle to predict metastasis
Merck CEO Kenneth Frazier's exit from a presidential manufacturing council may go down as one of the most principled stands by the CEO of a major U.S. company, let alone a drugmaker.